Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

BACKGROUND: Ripretinib 150 mg once daily (QD) is indicated for advanced gastrointestinal stromal tumors (GISTs) as at least fourth‐line therapy. In INVICTUS, ripretinib intrapatient dose escalation (IPDE) to 150 mg b.i.d. was allowed after progressive disease (PD) on 150 mg QD by blinded independent...

Descripción completa

Detalles Bibliográficos
Autores principales: Zalcberg, John R., Heinrich, Michael C., George, Suzanne, Bauer, Sebastian, Schöffski, Patrick, Serrano, César, Gelderblom, Hans, Jones, Robin L., Attia, Steven, D'Amato, Gina, Chi, Ping, Reichardt, Peter, Somaiah, Neeta, Meade, Julie, Reichert, Vienna, Shi, Kelvin, Sherman, Matthew L., Ruiz‐Soto, Rodrigo, von Mehren, Margaret, Blay, Jean‐Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Sarcomas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571742/
https://www.ncbi.nlm.nih.gov/pubmed/34313371
http://dx.doi.org/10.1002/onco.13917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571742/
https://www.ncbi.nlm.nih.gov/pubmed/34313371
http://dx.doi.org/10.1002/onco.13917

Ejemplares similares